港股異動丨信義能源(3868.HK)一度大漲8%再度破頂 8月以來獲南下資金持續加倉
格隆匯9月15日丨信義能源(3868.HK)延續強勢,盤中一度大漲8%再創新高。現漲幅收窄至3.97%,報3.14港元,暫成交3834萬港元,最新總市值208億港元。信義能源昨日公佈,計劃配售3.58億股,每股2.5港元。其中由國壽集團認購1.25億股,及私募基金高瓴資本認購2.33億股。昨日股價盤中一度大漲超17%,收漲11%。據格隆匯APP顯示,自8月以來獲南下資金持續加倉,港股通持倉比列自8月的0.42%升至目前最新的1.4%。新華匯富金融曾予目標價4.10港元,預計公司在20-22財年裝機容量的複合增長率為28%,至2022年底時將達到3.1GW。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.